secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMICUS THERAPEUTICS, INC. (—)
CIK:        0001178879
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088576
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amicus Q2 rev $94.5M (+17% YoY); raises Galafold guidance to 14-18% growth; CFO Quimi to retire
--------------------------------------------------------------------------------

- Q2 2023 total revenue $94.5M (+17% YoY at CER); net loss $43.2M ($0.15/sh), improved from $62.2M loss YoY.
- Full-year Galafold revenue growth guidance raised to 14-18% at CER; non-GAAP operating expense guidance cut to $330M-$350M.
- Company on track for non-GAAP profitability in H2 2023; expects U.S. and U.K. approvals of AT-GAA (Pombiliti+Opfolda) in Q3 2023.
- CEO Quimi to retire; CFO role search underway with identified candidates; she will stay until successor appointed.
- European launch of Pombiliti+Opfolda initiated in Germany; reimbursement discussions in additional EU countries ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178879/000110465923088576/0001104659-23-088576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178879/000110465923088576/tm2323120d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer